Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Articles

Page Path
HOME > Diabetes Metab J > Volume 31(3); 2007 > Article
Original Article Effects of Troglitazone on the Expression of VEGF and TGF-beta in Cultured Rat Mesangial Cells.
Dong Lim Kim, Nan Hee Kim, Dong Seop Choi
Diabetes & Metabolism Journal 2007;31(3):220-229
DOI: https://doi.org/10.4093/jkda.2007.31.3.220
Published online: May 1, 2007
  • 2,089 Views
  • 19 Download
  • 0 Crossref
  • 0 Scopus
1Department of Internal Medicine, Konkuk University School of Medicine, Korea.
2Department of Internal Medicine, College of Medicine, Korea University, Korea.

BACKGROUND
Clinical study reported that troglitazone ameliorated microalbuminuria in diabetic nephropathy. However, the mechanism of action is not fully understood. Vascular endothelial growth factor (VEGF) is known as vascular permeability factor and it is considered the most likely cause of glomerular hyperfiltration and proteinuria in diabetic nephropathy. Transforming growth factor-beta (TGF-beta) is a potent inducer of extracellular matrix production and fibrosis in renal cells and one of the important cytokine in the pathogenesis of diabetic nephropathy. To determine whether troglitazone affects VEGF and TGF-beta production in diabetic nephropathy, we examined the effects of troglitazone on the VEGF and TGF-beta expression in cultured rat mesangial cells exposed to high glucose concentration. METHODS: Rat mesangial cells were cultured in media with D-glucose 5.5 mM (NG) or D-glucose 30 mM (HG), or D-glucose 30 mM/troglitazone 20 micrometer(HTz) and for 6, 24, or 72 hours, respectively. VEGF and TGF-beta expression were assessed by semiquantitative RT-PCR and western blot analysis. RESULTS: Troglitazone decreased the VEGF164 and VEGF120 mRNA expressions in cultured rat mesangial cells exposed to high glucose concentration with incubation for 24 and 72 hours, respectively. VEGF protein was also decreased in experimental group treated with troglitazone (HTz) than in those with HG for 24 and 72 hours. However troglitazone had no effect on the expression of TGF-beta mRNA in mesangial cells. CONCLUSION: This study suggested that troglitazone may modulate the development and progression of diabetic nephropathy by reducing the expression of VEGF in mesangial cells

  • Cite
    CITE
    export Copy
    Close
    Download Citation
    Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

    Format:
    • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
    • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
    Include:
    • Citation for the content below
    Effects of Troglitazone on the Expression of VEGF and TGF-beta in Cultured Rat Mesangial Cells.
    Korean Diabetes J. 2007;31(3):220-229.   Published online May 1, 2007
    Close
Related articles
Kim DL, Kim NH, Choi DS. Effects of Troglitazone on the Expression of VEGF and TGF-beta in Cultured Rat Mesangial Cells.. Diabetes Metab J. 2007;31(3):220-229.
DOI: https://doi.org/10.4093/jkda.2007.31.3.220.

Diabetes Metab J : Diabetes & Metabolism Journal